Flow-injection chemiluminescence determination of olanzapine using N-chlorosuccinimide-calcein reaction sensitized by zinc (II)

Integrated spectroscopic approaches for the facile one pot quantification of olanzapine in pharmaceutical formulation and spiked human plasma

In this work, the xanthene dye, erythrosine B, was employed as a probe for the determination of olanzapine using two fast and highly simple analytical approaches. The assay was based on the formation of a binary complex between the drug and erythrosine B in a slightly acidic aqueous buffered solution. In the first method, the absorbance of the formed product was monitored at 558 nm. The reaction stoichiometry was investigated, and the stability constant of the formed complex was estimated. The linear range of the method that obeyed Beer's law was in the concentration range of 0.6-8.0 µg/ml. The calculated detection and quantitation limits were 0.2 and 0.6 µg/mL. Upon adding the drug solution to erythrosine B, the native fluorescence of the dye was quenched and monitored at 550 nm after excitation at 528 nm. Thus, the fluorescence quenching was utilized as the quantitative signal in the spectrofluorimetric approach. The extent of quenching in the fluorescence intensity was rectilinear with the drug concentration in a range of 0.1-2.5 µg/ml with a detection limit of 0.032 µg/ml. Both approaches were analytically validated based on the guiding rules of the ICH with acceptable results, and were utilized efficiently in the analysis of olanzapine in commercial tablets containing the cited drug. In addition, owing to its high sensitivity and selectivity, the spectrofluorimetric method was applied for drug analysis in spiked human plasma with satisfactory % recoveries. Finally, the greenness of the methods was confirmed using eco-score scale and Analytical Green Evaluation metrics.

Dual Fluorescence-colorimetric Silver Nanoparticles Based Sensor for Determination of Olanzapine: Analysis in Rat Plasma and Pharmaceuticals

The present work describes a dual-readout assay for the determination of an antipsychotic drug olanzapine using Rhodamine B modified silver nanoparticles (AgNPs). AgNPs, when mixed with Rhodamine B, quenched its fluorescence emission with high quenching efficiency as evident from the Stern Volmer plot. Transmission electron microscopy image and Dynamic Light Scattering histogram of Rhodamine B bound AgNPs showed a stable monodispersed nanosuspension. Addition of olanzapine to Rhodamine B-bound AgNPs resulted in reappearance of fluorescence, which was dependent on the amount of olanzapine added to the system. Besides displacing the surface bound Rhodamine B molecules, it caused aggregation of AgNPs which formed the basis of dual-readout sensor. Several parameters such as pH, reaction time and order of addition of the three components which may influence the analytical signal were studied and optimized. The method was validated for linearity, sensitivity, selectivity, accuracy, precision and recovery. Based on this dual-readout system, linear concentration range was established from 0.05 to 10 µM (fluorescence measurement) and 5.0 to 50 µM (colorimetric response) for olanzapine. The limit of detection (LOD) using fluorescence and colorimetric approach was 0.013 µM and 1.25 µM, respectively. The proposed method showed excellent selectivity for olanzapine in presence of several antipsychotic drugs, cations, sugars and amino acids. Finally, the method was successfully applied to a pharmacokinetic study of olanzapine in rats and also for analyzing pharmaceutical formulations.

'Turn-on' fluorescent chemosensors based on naphthaldehyde-2-pyridinehydrazone compounds for the detection of zinc ion in water at neutral pH

A series of naphthaldehyde-2-pyridinehydrazone derivatives were discovered to display interesting 'turn-on' fluorescence response to Zn²⁺ in 99% water/DMSO (v/v) at pH 7.0. Mechanism study indicated that different substituent groups in the naphthaldehyde moiety exhibited significant influence on the detection of Zn²⁺ . The electron rich group resulted in longer fluorescence wavelengths but smaller fluorescence enhancement for Zn²⁺ . Among these compounds, 1 showed the highest fluorescence enhancement of 19-fold with the lowest detection limit of 0.17 μmol/L toward Zn²⁺ . The corresponding linear range was at least from 0.6 to 6.0 μmol/L. Significantly, 1 showed an excellent selectivity toward Zn²⁺ over other metal ions including Cd²⁺ .

Development of a new procedure for the determination of captopril in pharmaceutical formulations employing chemiluminescence and a multicommuted flow analysis approach

This paper describes a new technique for the determination of captopril in pharmaceutical formulations, implemented by employing multicommuted flow analysis. The analytical procedure was based on the reaction between hypochlorite and captopril. The remaining hypochlorite oxidized luminol that generated electromagnetic radiation detected using a homemade luminometer. To the best of our knowledge, this is the first time that this reaction has been exploited for the determination of captopril in pharmaceutical products, offering a clean analytical procedure with minimal reagent usage. The effectiveness of the proposed procedure was confirmed by analyzing a set of pharmaceutical formulations. Application of the paired t-test showed that there was no significant difference between the data sets at a 95% confidence level. The useful features of the new analytical procedure included a linear response for captopril concentrations in the range 20.0-150.0 µmol/L (r = 0.997), a limit of detection (3σ) of 2.0 µmol/L, a sample throughput of 164 determinations per hour, reagent consumption of 9 µg luminol and 42 µg hypochlorite per determination and generation of 0.63 mL of waste. A relative standard deviation of 1% (n = 6) for a standard solution containing 80 µmol/L captopril was also obtained.

Molecularly imprinted polymer nanoparticles for olanzapine recognition: application for solid phase extraction and sustained release

The aim of this study was to prepare efficient imprinted polymer nanoparticles from an olanzapine template for the controlled release of olanzapine as a therapeutic drug for CNS diseases.